# IMbrave251 (NCT04770896)

> A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04770896
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Unresectable Hepatocellular Carcinoma
- Interventions: Atezolizumab; Lenvatinib; Sorafenib
- Enrollment: 557
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 18
- Podcasts: 10
- YouTube: 9

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=imbrave251-nct04770896

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04770896", "email": "<work email>"}; the inbox owner confirms by the emailed link.